Comparative efficacy of axitinib versus sorafenib for advanced renal cell carcinoma

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Rini, Brian I.
    Escudier, Bernard
    Tomczak, Piotr
    Kaprin, Andrey
    Szczylik, Cezary
    Hutson, Thomas E.
    Michaelson, M. Dror
    Gorbunova, Vera A.
    Gore, Martin E.
    Rusakov, Igor G.
    Negrier, Sylvie
    Ou, Yen-Chuan
    Castellano, Daniel
    Lim, Ho Yeong
    Uemura, Hirotsugu
    Tarazi, Jamal
    Cella, David
    Chen, Connie
    Rosbrook, Brad
    Kim, Sinil
    Motzer, Robert J.
    LANCET, 2011, 378 (9807): : 1931 - 1939
  • [2] Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
    Kenney, Patrick A.
    Wood, Christopher G.
    EUROPEAN UROLOGY, 2012, 62 (01) : 182 - 183
  • [3] Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Wang, Hai
    Man, Libo
    Li, Guizhong
    Huang, Guanglin
    Wang, Jianwei
    ONCOTARGETS AND THERAPY, 2016, 9 : 3423 - 3432
  • [4] Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (02): : 412 - 413
  • [5] Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
    Gunnarsson, Orvar
    Pfanzelter, Nicklas R.
    Cohen, Roger B.
    Keefe, Stephen M.
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 65 - 73
  • [6] Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
    B Escudier
    M D Michaelson
    R J Motzer
    T E Hutson
    J I Clark
    H Y Lim
    E Porfiri
    P Zalewski
    G Kannourakis
    M Staehler
    J Tarazi
    B Rosbrook
    L Cisar
    S Hariharan
    S Kim
    B I Rini
    British Journal of Cancer, 2014, 110 : 2821 - 2828
  • [7] Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
    Escudier, B.
    Michaelson, M. D.
    Motzer, R. J.
    Hutson, T. E.
    Clark, J. I.
    Lim, H. Y.
    Porfiri, E.
    Zalewski, P.
    Kannourakis, G.
    Staehler, M.
    Tarazi, J.
    Rosbrook, B.
    Cisar, L.
    Hariharan, S.
    Kim, S.
    Rini, B. I.
    BRITISH JOURNAL OF CANCER, 2014, 110 (12) : 2821 - 2828
  • [8] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (vol 378, pg 1931, 2011)
    Rini, B., I
    Escudier, B.
    Tomczak, P.
    LANCET, 2012, 380 (9856): : 1818 - 1818
  • [9] Axitinib: A Review in Advanced Renal Cell Carcinoma
    Gillian M. Keating
    Drugs, 2015, 75 : 1903 - 1913
  • [10] Axitinib (Inlyta) for Advanced Renal Cell Carcinoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1392): : 47 - 48
12345